Navigation Links
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/13/2008

e year ended December 31, 2007 included:

-- a $20.2 million non-cash reduction in the carrying value of the

intangible asset related to Antizol(R) (fomepizole) as a result of the

approval and introduction of a generic competitor;

-- a $17.5 million charge related to a previously announced settlement

with the United States government, of which $1.0 million was paid in

2007;

-- $9.5 million of contract revenue resulting from milestone payments

under Jazz Pharmaceuticals' agreement with UCB; and

-- a $5.1 million gain on the divestiture of Cystadane(R) (betaine

anhydrous for oral solution).

Net loss for the year ended December 31, 2006 included a $31.6 million non-cash gain on extinguishment of a development financing obligation in connection with a terminated development program.

Research and development expenses for the quarter ended December 31, 2007 were $20.5 million, compared to $13.0 million for the quarter ended December 31, 2006. For the year ended December 31, 2007, research and development expenses were $69.8 million, compared to $55.0 million for the year ended December 31, 2006. The increase in research and development expenses in 2007 reflects expanded Phase III clinical trial activities for JZP-6, LUVOX CR scale-up and manufacturing costs and increased headcount.

Selling, general and administrative expenses for the quarter ended December 31, 2007 were $28.0 million, compared to $12.5 million for the quarter ended December 31, 2006. For the year ended December 31, 2007, selling, general and administrative expenses were $78.5 million, compared to $51.4 million for the year ended December 31, 2006. The increase in both periods was primarily due to spending in preparation for the anticipated launch of Once-A-Day LUVOX CR (fluvoxamine maleate) Extended-Release Capsules, increased headcount and higher expenses to support the company's sales force, offset
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
2. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
3. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
6. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
7. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
8. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
9. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
11. Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Malvern, PA & Brussels (PRWEB) December 22, 2014 ... Education (CfPIE), the global leader of technical training ... Society for Clinical Data Management (SCDM) to ... training and certification programs —providing access to the ... The partnership extends SCDM members with 10% off when ...
(Date:12/22/2014)... 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, announced today ... of Calgary in conjunction with co-authors from Kyoto University ... the company,s ongoing clinical research using dermal sheath cup ... The paper entitled " Hair Follicle Dermal ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/22/2014)... The American Journal of ... research, reviews and editorials addressing developments and pathways ... published a provocative article exploring the role of ... potential treatment of prostate cancer. , The ... the possibility that there could be a connection ...
Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... thing with IT shops right now. It's the new magic ... word and the music swells. Then we'll go skipping off ... happy customers. Yes, I was touting partnership just last week ... hard work. Partnership is the right relationship answer only if ...
... announced Wednesday it has been awarded a contract ... management hardware for a U.S. Department of Energy ... million project will develop, manufacture and demonstrate a mine ... metal-hydride storage and refueling hardware. , ,The project was ...
... Left to right: Professor James Dumesic, graduate students Steven ... researcher Won Bae Kim. Source: UW-Madison. MADISON - ... technical barrier to the efficient operation of fuel cells. ... of Wisconsin-Madison have not only cleared that barrier - ...
Cached Biology Technology:Blooming partnerships 2Blooming partnerships 3Blooming partnerships 4Modine Manufacturing to contribute to DOE's fuel-cell vehicle 2UW engineers clear bottleneck in hydrogen production 2
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ... beliefs about the condition and the best ways to treat ...
(Date:12/10/2014)... 2014 You,ve been here before: you desperately need ... your password, site key or the answer to your secret ... teacher? Today, Hoyos Labs , a ... will finally put an end to the frustration that comes ... . 1U leverages a user,s smartphone to acquire his or ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... 6, 2011 Ceelox, Inc. (OTCBB: CELO) announced today ... which operates on computers running the Windows 7 Operating ... their authentication approach to leverage the recent capability of ... (WBF) provides support for fingerprint biometric devices through a ...
... an alternative to drugs for the prevention of esophageal ... Annual Meeting 2011, held here April 2-6. ... eating strawberries is safe and easy to consume. In ... histological grade of precancerous lesions and reduce cancer-related molecular ...
... That,s the agonizing choice some birds face, according to ... by Guelph researchers discovered that for some male birds traveling ... attracting a female when they return home. Alice Boyle, a ... Chris Guglielmo, a biologist at the University of Western Ontario, ...
Cached Biology News:Ceelox Offers Beta Release of Ceelox ID 7 for Personal Computers 2Strawberries may slow precancerous growth in esophagus 2Birds must choose between mating, migrating, study finds 2
Request Info...
Polyclonal Antibody to CLAN...
Goat polyclonal to MLH3 ( Abpromise for all tested applications). entrezGeneID: 27030 SwissProtID: Q9UHC1...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biology Products: